**Background**
Toxoplasmosis is a parasitic disease caused by the protozoan Toxoplasma gondii, which can infect nearly all warm-blooded animals, including humans. In immunocompromised individuals or during congenital transmission, the infection can lead to severe neurological and ocular complications. The management of this disease typically requires the inhibition of folate synthesis within the parasite to prevent DNA replication and cellular proliferation. Consequently, targeting the folate pathway remains a cornerstone of therapeutic strategies for treating toxoplasmosis. In this context, we will introduce a sulfonamide antibiotic with potent antimalarial and antiparasitic activity – Sulfadiazine.
**Definition**
Sulfadiazine is a sulfonamide antibiotic used primarily in toxoplasmosis research, exhibiting antimicrobial activity against various Toxoplasma gondii isolates with IC50 values ranging from 2.95 mg/L to over 50 mg/L depending on the strain.
**In Vitro and In Vivo Studies**
The Sulfadiazine biological activity has been extensively evaluated across multiple cell lines and animal models. Sulfadiazine in vitro studies using human MRC-5 cells infected with different Toxoplasma gondii isolates after 72 hours revealed varying levels of susceptibility. For instance, the isolate TOU-1998-TRI showed high susceptibility with an IC50 of 2.95 mg/L, while the ME49 strain exhibited an IC50 of 6.55 mg/L. In contrast, some strains, such as B1 and RMS-2001-MAU, demonstrated significantly lower susceptibility with IC50 values exceeding 50 mg/L. Additionally, tests in Vero cells showed IC50 values of 0.09 mM and 0.1 mM against intracellular parasites after 24 hours.
Regarding Sulfadiazine In Vivo efficacy, research utilizing Swiss mice infected with seven atypical T. gondii strains evaluated the drug at dosages ranging from 10 to 640 mg/kg per day. The results indicated that susceptibility is highly genotype-dependent; for example, the TgCTBr9 strain (genotype 11) showed high susceptibility to treatment, whereas the TgCTBr4 and TgCTBr17 strains (genotype 108) presented lower susceptibility. Furthermore, the combination of Sulfadiazine with Pyrimetamine was found to be effective even at lower individual dosages. For researchers seeking detailed Sulfadiazine technical information, these findings highlight the importance of strain-specific responses in therapeutic outcomes. In conclusion, Sulfadiazine is a versatile sulfonamide antibiotic that serves as a critical tool for studying the treatment and resistance mechanisms of Toxoplasma gondii.
Keywords
Sulfadiazine, 68-35-9, Bacterial, Parasite, Antibiotic, sulfonamide, antibiotic, veterinary, pig, toxoplasmosis, Inhibitor, inhibitor, inhibit
References
[1] Kopmann C, et al. Abundance and transferability of antibiotic resistance as related to the fate of sulfadiazine in maize rhizosphere and bulk soil. FEMS Microbiol Ecol. 2013 Jan;83(1):125-34.
[2] Silva LA, et al. Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil. Exp Parasitol. 2019 Jul;202:7-14.